Epidemiology of diabetic retinopathy: expected vs reported prevalence of cases in the French population.

AIM AND METHODS Impaired eyesight and vision loss due to retinopathy are among the most feared complications in diabetic patients. As the number of diabetic patients is predicted to increase, a corresponding increase in the number of patients with diabetic retinopathy (DR) is also to be expected. This review is an update of the published literature pertaining to the epidemiology of DR. RESULTS Over the past 20 years, eight population-based studies have been conducted in Western countries using photographic evidence of DR. Their results have consistently suggested that the prevalence of DR is close to 28.7%, whereas proliferative DR and macular oedema account for 9% and 17%, respectively, of all diagnosed cases. Various longitudinal studies indicate an annual incidence of DR of 2-6%. However, in France, the epidemiology of DR has mostly been investigated by observational studies. The recorded prevalence of DR, based on physicians' reports, is estimated to be 10%, suggesting that DR is underdiagnosed in the French diabetic population. The discrepancy between the expected and reported prevalences of DR could be explained by the number of patients whose retinal status is unknown. DR screening with non-mydriatic fundus photography is effective for identifying early and advanced DR. Screening programmes carried out over the past 5 years in different regions of France indicate that 10-20% of diabetic patients with previously unknown retinal status have retinopathy. CONCLUSION Further implementation of screening programmes is the key to improving DR diagnosis and preventing vision loss in the French diabetic population.

[1]  Beverley Balkau,et al.  The prevalence of and factors associated with diabetic retinopathy in the Australian population. , 2003, Diabetes care.

[2]  H. Taylor,et al.  Five‐year incidence of diabetic retinopathy in the Melbourne Visual Impairment Project , 2003, Clinical & experimental ophthalmology.

[3]  Stephen J. Aldington,et al.  UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.

[4]  C. Delcourt,et al.  Low prevalence of long-term complications in non-insulin-dependent diabetes mellitus in France: a multicenter study. CODIAB-INSERM-ZENECA Pharma Study Group. , 1998, Journal of diabetes and its complications.

[5]  D. Reda,et al.  Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. , 2005, Diabetes care.

[6]  The National Screening Committee review of diabetic retinopathy screening. , 2001 .

[7]  J. J. Wang,et al.  Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. , 1998, Ophthalmology.

[8]  J. Jacob,et al.  Longitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme , 2002, Eye.

[9]  G. Dardanoni,et al.  Prevalence and risk factors of diabetic retinopathy in adult and elderly subjects: The Casteldaccia Eye Study , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[10]  U. Högberg,et al.  The World Health report 2002. , 2003, Midwifery.

[11]  T. Bek,et al.  The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. , 2004, Acta ophthalmologica Scandinavica.

[12]  B. Charbonnel,et al.  Managing type 2 diabetes in France: the ECODIA survey. , 2000, Diabetes & metabolism.

[13]  D. Simon,et al.  Management of diabetic patients by general practitioners in France 1997: an epidemiological study. , 2000, Diabetes & metabolism.

[14]  S. Resnikoff,et al.  Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.

[15]  C. Delcourt,et al.  Clinical correlates of advanced retinopathy in type II diabetic patients: implications for screening. The CODIAB-INSERM-Zeneca Pharma Study Group. , 1996, Journal of clinical epidemiology.

[16]  J. Forrester,et al.  Epidemiology of diabetic retinopathy and macular oedema: a systematic review , 2004, Eye.

[17]  F. Ferris,et al.  Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. , 1998, Investigative ophthalmology & visual science.

[18]  T. Wong,et al.  Management of diabetic retinopathy: a systematic review. , 2007, JAMA.

[19]  J. Shaw,et al.  Longitudinal Association of Glucose Metabolism With Retinopathy , 2008, Diabetes Care.

[20]  C. Creuzot-Garcher,et al.  Dépistage de larétinopathie diabétique en Bourgogne par un rétinographe non mydriatique itinérant , 2007 .

[21]  H. Taylor,et al.  Diabetic retinopathy in Victoria, Australia: the Visual Impairment Project , 2000, The British journal of ophthalmology.

[22]  D. DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. , 1984, Archives of ophthalmology.

[23]  Peter E. Hilsenrath,et al.  The World Health Report 2000 , 2002 .

[24]  Cécile Delcourt,et al.  Visual impairment in Type 2 diabetic patients , 1995 .

[25]  J. Sahel,et al.  [Detection, monitoring and treatment of diabetic retinopathy. Recommendations of ALFEDIAM. Committee of above-mentioned experts and validated by the board of directors and scientific board of ALFEDIAM]. , 1996, Diabetes & metabolism.

[26]  R. Bourrel,et al.  Les modalités de suivi des diabétiques non insulino traités en France métropolitaine durant l'année 1998 , 2008 .

[27]  Simon P Harding,et al.  Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study , 2003, The Lancet.

[28]  Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. , 1995, Ophthalmology.

[29]  A. Erginay,et al.  OPHDIAT: a telemedical network screening system for diabetic retinopathy in the Ile-de-France. , 2008, Diabetes & metabolism.

[30]  Epidemiological analysis of patients with Type 2 diabetes in France. , 2000, Journal of diabetes and its complications.

[31]  S. Harding,et al.  Incidence of sight‐threatening retinopathy in Type 1 diabetes in a systematic screening programme , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[32]  J. J. Wang,et al.  Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study , 2007, Eye.

[33]  A. Girach,et al.  Diagnosed diabetic retinopathy in France, Italy, Spain, and the United Kingdom. , 2007, Primary care diabetes.

[34]  M. D. Wilson GUIDE - AFFECTION DE LONGUE DURÉE , 2008 .

[35]  Marie Restori,et al.  Échographie en Ophtalmologie , 1986 .

[36]  D L DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. , 1984, Archives of ophthalmology.

[37]  R. Klein,et al.  Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials , 2008, The Lancet.

[38]  A. Erginay,et al.  Evaluation of a screening program for diabetic retinopathy in a primary care setting Dodia (Dépistage ophtalmologique du diabète) study. , 2005, Diabetes & metabolism.

[39]  R. Klein,et al.  Diabetic retinopathy in a multi-ethnic cohort in the United States. , 2006, American journal of ophthalmology.

[40]  R. Klein,et al.  The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. , 1992, Ophthalmology.

[41]  H. Parving,et al.  Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. , 2003, Diabetes care.

[42]  C. Delcourt,et al.  Visual impairment in type 2 diabetic patients. A multicentre study in France. CODIAB-INSERM-ZENECA Pharma Study Group. , 1995, Acta ophthalmologica Scandinavica.